Spanish biotech company AB-Biotics and Scienta Farma reached an agreement to sell the pharmacogenetic test Neurofarmagen in Mexico. This test, developed by AB-Biotics, identifies the most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing DNA, extracted from a saliva sample.
Scienta Farma will have exclusive rights to distribute Neurofarmagen in Mexico. Mexico is the third country to launch Neurofarmagen. The test already is sold in Spain, marketed by Almirall, and in Brazil through GlaxoSmithKline. Over 33 million people suffer from mental disorder in Mexico, according to National Comorbidity Survey, and 60% (13.3 million patients) are being treated.